FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer
January 13, 2016
DelMar Pharmaceuticals, Inc. - "Modernizing Medicines: DelMar’s Strategic Edge for VAL-083 in Oncology"
January 08, 2016
StockNewsNow.com Publishes New SNNLive Video Interview With DelMar Pharmaceuticals, Inc.
January 06, 2016
DelMar Pharmaceuticals to Present at the Biotech Showcase™ 2016 on January 12, 2016
January 05, 2016
A Look at Four Brain Cancer Companies for 2016
January 04, 2016
SeeThruEquity Issues Update on DelMar Pharmaceuticals Increasing Price Target to $5.75 Per Share and Highlighting Encouraging Data from Phase 2 Clinical Study of VAL-083
December 03, 2015
category Banking & Financial Services
Maxim Group Reiterates BUY Rating for DelMar Pharmaceuticals, Inc. and Provides Company Update
November 24, 2015
DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting
November 23, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here